Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for enVVeno Medical Corporation (NVNO : NSDQ)

• Company Description    enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $10.39 Daily Weekly Monthly 20 Day Moving Average: 23,335 shares Shares Outstanding: 0.67 (millions) Market Capitalization: $6.94 (millions) Beta: 1.09 52 Week High: $184.45 52 Week Low: $8.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.15% -4.90% 12 Week -1.05% -3.48% Year To Date -7.69% -14.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 70 DOPPLER - IRVINE,CA 92618 USA ph: 949-261-2900 fax: 949-261-2992 nvno@jtcir.com http://www.envveno.com

• General Corporate Information    Officers Robert Berman - Chief Executive Officer Jennifer Bright - Chief Financial Officer Marc H. Glickman - Senior Vice President Hamed Alavi - Senior Vice President Francis Duhay - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 29415J205 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 0.67 Most Recent Split Date: 1.00 (0.03:1) Beta: 1.09 Market Capitalization: $6.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-16.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 23.70% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -66.39 12/31/25 - -60.88 ROA 06/30/26 - - 03/31/26 - -60.42 12/31/25 - -56.01 Current Ratio 06/30/26 - - 03/31/26 - 11.89 12/31/25 - 13.58 Quick Ratio 06/30/26 - - 03/31/26 - 11.89 12/31/25 - 13.58 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 36.23 12/31/25 - 41.38 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©